epocrates logo
epocrates logo
epocrates logo
  • 0

Government Health Agency News

FDA

Risk of dissolution failure prompts recall of potassium chloride ER capsules

June 26, 2024

card-image

Glenmark Pharmaceuticals is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K that are used for the treatment of hypokalemia. The product is being recalled because of failed dissolution of the capsules, which may cause hyperkalemia and potentially lead to cardiac arrhythmias, severe muscle weakness, and death. To date, there have been no reports of hyperkalemia or serious adverse events related to this recall.

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information